Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study
(2022) In Breast Cancer Research and Treatment 191(3). p.611-621- Abstract
Purpose: Examine the association between circulating lipids and breast cancer outcomes in patients enrolled in the Malmö Diet and Cancer Study (MDCS). Patients and methods: Circulating lipid levels were measured in blood sampled upon enrollment in the female MDCS cohort (N = 17,035). We identified all MDCS participants with incident invasive breast cancer diagnosed between 1991 and 2014. Follow-up time began at breast cancer diagnosis and continued until the first event of breast cancer recurrence, death, emigration, or 5 years of follow-up. We estimated the incidence rates of recurrence at 5 years and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI) of breast cancer... (More)
Purpose: Examine the association between circulating lipids and breast cancer outcomes in patients enrolled in the Malmö Diet and Cancer Study (MDCS). Patients and methods: Circulating lipid levels were measured in blood sampled upon enrollment in the female MDCS cohort (N = 17,035). We identified all MDCS participants with incident invasive breast cancer diagnosed between 1991 and 2014. Follow-up time began at breast cancer diagnosis and continued until the first event of breast cancer recurrence, death, emigration, or 5 years of follow-up. We estimated the incidence rates of recurrence at 5 years and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI) of breast cancer recurrence as well as all-cause mortality according to cohort-specific tertiles of apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B). Results: We enrolled 850 eligible patients. During the 5 years of follow-up, 90 invasive breast cancer recurrences were diagnosed over 3807 person-years. In multivariable analyses, high baseline levels of Apo B were associated with an increased rate of recurrence (tertile 3 vs. 1, HR = 2.30 [95% CI 1.13–4.68]). However, high baseline levels of Apo B were not associated with all-cause mortality (tertile 3 vs. 1, HR = 1.23 [95% CI 0.68–2.25]). We observed no associations between levels of Apo A-1 and recurrence (tertile 3 vs. 1, HR = 1.34 [95% CI 0.70–2.58]) or all-cause mortality (tertile 3 vs. 1, HR = 1.12 [95% CI 0.61–2.05]). Conclusion: High pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. Circulating Apo A-1 was not associated with breast cancer outcomes.
(Less)
- author
- Harborg, Sixten ; Ahern, Thomas P. ; Feldt, Maria LU ; Rosendahl, Ann H. LU ; Cronin-Fenton, Deirdre ; Melander, Olle LU and Borgquist, Signe LU
- organization
-
- Breast cancer prevention & intervention (research group)
- LUCC: Lund University Cancer Centre
- MultiPark: Multidisciplinary research focused on Parkinson´s disease
- EXODIAB: Excellence of Diabetes Research in Sweden
- EpiHealth: Epidemiology for Health
- Cardiovascular Research - Hypertension (research group)
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- All-cause mortality, Apolipoprotein A1, Apolipoprotein B, Apolipoproteins, Breast cancer, Cancer, Circulating lipids, Cohort study, Distant recurrence, Dyslipidemia, Lipids, Loco-regional recurrence, Prognosis, Recurrence, Survival
- in
- Breast Cancer Research and Treatment
- volume
- 191
- issue
- 3
- pages
- 611 - 621
- publisher
- Springer
- external identifiers
-
- scopus:85119846318
- pmid:34825306
- ISSN
- 0167-6806
- DOI
- 10.1007/s10549-021-06462-7
- language
- English
- LU publication?
- yes
- id
- 1443a5c5-71ac-420a-986b-6e6417b1a1d2
- date added to LUP
- 2021-12-15 08:33:14
- date last changed
- 2024-09-22 07:41:33
@article{1443a5c5-71ac-420a-986b-6e6417b1a1d2, abstract = {{<p>Purpose: Examine the association between circulating lipids and breast cancer outcomes in patients enrolled in the Malmö Diet and Cancer Study (MDCS). Patients and methods: Circulating lipid levels were measured in blood sampled upon enrollment in the female MDCS cohort (N = 17,035). We identified all MDCS participants with incident invasive breast cancer diagnosed between 1991 and 2014. Follow-up time began at breast cancer diagnosis and continued until the first event of breast cancer recurrence, death, emigration, or 5 years of follow-up. We estimated the incidence rates of recurrence at 5 years and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI) of breast cancer recurrence as well as all-cause mortality according to cohort-specific tertiles of apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B). Results: We enrolled 850 eligible patients. During the 5 years of follow-up, 90 invasive breast cancer recurrences were diagnosed over 3807 person-years. In multivariable analyses, high baseline levels of Apo B were associated with an increased rate of recurrence (tertile 3 vs. 1, HR = 2.30 [95% CI 1.13–4.68]). However, high baseline levels of Apo B were not associated with all-cause mortality (tertile 3 vs. 1, HR = 1.23 [95% CI 0.68–2.25]). We observed no associations between levels of Apo A-1 and recurrence (tertile 3 vs. 1, HR = 1.34 [95% CI 0.70–2.58]) or all-cause mortality (tertile 3 vs. 1, HR = 1.12 [95% CI 0.61–2.05]). Conclusion: High pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. Circulating Apo A-1 was not associated with breast cancer outcomes.</p>}}, author = {{Harborg, Sixten and Ahern, Thomas P. and Feldt, Maria and Rosendahl, Ann H. and Cronin-Fenton, Deirdre and Melander, Olle and Borgquist, Signe}}, issn = {{0167-6806}}, keywords = {{All-cause mortality; Apolipoprotein A1; Apolipoprotein B; Apolipoproteins; Breast cancer; Cancer; Circulating lipids; Cohort study; Distant recurrence; Dyslipidemia; Lipids; Loco-regional recurrence; Prognosis; Recurrence; Survival}}, language = {{eng}}, number = {{3}}, pages = {{611--621}}, publisher = {{Springer}}, series = {{Breast Cancer Research and Treatment}}, title = {{Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study}}, url = {{http://dx.doi.org/10.1007/s10549-021-06462-7}}, doi = {{10.1007/s10549-021-06462-7}}, volume = {{191}}, year = {{2022}}, }